A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Japanese Adults
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs AZD 5148 (Primary) ; AZD 5148 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions
- Sponsors AstraZeneca
- 21 Nov 2024 Planned End Date changed from 12 Jan 2026 to 13 Jan 2026.
- 21 Nov 2024 Status changed from not yet recruiting to recruiting.
- 17 Oct 2024 New trial record